2-[N-(6-benzyloxy-2,5,7,8-tetramethylchroman-2-ylmethyl)-N-methylamino]ethyl chloride | 187340-97-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2-[N-(6-benzyloxy-2,5,7,8-tetramethylchroman-2-ylmethyl)-N-methylamino]ethyl chloride
• 英文别名: 2-[N-(6-Benzyloxy-2,5,7,8-tetramethylchroman-2ylmethyl)-N-methylamino]ethyl chloride；2-chloro-N-methyl-N-[(2,5,7,8-tetramethyl-6-phenylmethoxy-3,4-dihydrochromen-2-yl)methyl]ethanamine
• CAS: 187340-97-2
• 化学式: C₂₄H₃₂ClNO₂
• 分子量: 401.977
• InChiKey: LEVZZZHXELNWBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[N-(6-benzyloxy-2,5,7,8-tetramethylchroman-2-ylmethyl)-N-methylamino]ethyl chloride 在 palladium on activated charcoal 氢溴酸 、 氢气 、 potassium carbonate 、 sodium nitrite 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 5.0~80.0 ℃ 、413.68 kPa 条件下， 反应 12.5h， 生成 ethyl 2-bromo-3-[4-[2-[N-(6-benzyloxy-2,5,7,8-tetramethylchroman-2-ylmethyl)-N-methylamino]ethoxy]phenyl]propanoate
  参考文献：
  名称：

  Novel Antidiabetic and Hypolipidemic Agents. 5. Hydroxyl versus Benzyloxy Containing Chroman Derivatives

  摘要：

  Several thiazolidinediones having chroman moieties were synthesized and evaluated for their euglycemic and hypolipidemic activities. Some of the analogues having an aminoalkyl group as a linker between the chroman ring and 4-[5-(2,4-dioxo-1,3-thiazolidinyl)methyl]phenoxy moiety seem to be better than troglitazone. In vitro transactivation assays of PPAR gamma have been carried out with these glitazones to understand their molecular mechanism. For the first time we have found that some of the unsaturated thiazolidinediones are superior to their saturated counterpart in the in vivo assay. A more potent thiazolidinedione analogue than troglitazone is reported. Pharmacokinetic studies have shown that protection of the OH group in the chroman moiety leads to a decrease in metabolism, thereby resulting in a superior pharmacological profile.

  DOI：

  10.1021/jm9805541
• 作为产物：
  描述：

  (2R/S)-[6-benzyloxy-2,5,7,8-tetramethylchroman-2-yl]carbinol 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 2-[N-(6-benzyloxy-2,5,7,8-tetramethylchroman-2-ylmethyl)-N-methylamino]ethyl chloride
  参考文献：
  名称：

  Novel Antidiabetic and Hypolipidemic Agents. 5. Hydroxyl versus Benzyloxy Containing Chroman Derivatives

  摘要：

  Several thiazolidinediones having chroman moieties were synthesized and evaluated for their euglycemic and hypolipidemic activities. Some of the analogues having an aminoalkyl group as a linker between the chroman ring and 4-[5-(2,4-dioxo-1,3-thiazolidinyl)methyl]phenoxy moiety seem to be better than troglitazone. In vitro transactivation assays of PPAR gamma have been carried out with these glitazones to understand their molecular mechanism. For the first time we have found that some of the unsaturated thiazolidinediones are superior to their saturated counterpart in the in vivo assay. A more potent thiazolidinedione analogue than troglitazone is reported. Pharmacokinetic studies have shown that protection of the OH group in the chroman moiety leads to a decrease in metabolism, thereby resulting in a superior pharmacological profile.

  DOI：

  10.1021/jm9805541

文献信息

• Thiazolidinedione derivatives having antidiabetic, hypolipidaemic antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：EP0801063A1

  公开（公告）日：1997-10-15

  A compound of the general formula (I), where A represents, substituted or unsunstituted unsaturated aliphatic, alicyclic, aromatic, heterocyclic groups, B represents a substituted or unsubstituted divalent alkylene or alkenyl group having 1 to 10 carbon atoms, wherein substituents may be present in one or more of the divalent alkylene or alkenyl groups, D represents a substituted or insubstituted divalent alkenyl, alkynyl, aralkyl alkoxycarbonyl or aryloxycarbonyl groups, X represents CH2, C=O, CH-OH, sulphur, oxygen, N-Y, where Y represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl or acyl, Ar represents a divalent aromatic, single or fused ring system, with or without substituents, the ring may contain one or more hetero atoms selected from nitrogen, sulphur, or oxygen; R1 and R2 each represents hydrogen or together represent a bond either or both may be substituents or both together form a part of a ring. Methods for preparing the compound and pharmaceutical compositions containing a compound of formula (I).

  通式(I)的化合物、 其中 A 代表取代或未取代的不饱和脂肪族、脂环族、芳香族、杂环族基团，B 代表具有 1 至 10 个碳原子的取代或未取代的二价亚烷基或烯基，其中取代基可存在于一个或多个二价亚烷基或烯基之中，D 代表取代或未取代的二价烯基、炔基、芳烷基烷氧基羰基或芳氧基羰基，X 代表 CH2、C=O、CH-OH、硫、氧、烷氧基羰基、芳烷氧基羰基或芳氧基羰基、X代表CH2、C＝O、CH-OH、硫、氧、N-Y，其中Y代表氢、取代或未取代的烷基、芳基、芳烷基或酰基，Ar代表二价芳香族、单环或熔合环体系，带或不带取代基，环中可含有一个或多个选自氮、硫或氧的杂原子；R1 和 R2 各自代表氢，或共同代表键，或两者均为取代基，或两者共同构成环的一部分。制备化合物和含有式（I）化合物的药物组合物的方法。
• Novel euglycemic and hypolipidemic agents: Part - 2 antioxidant moiety as structural motif
  作者：K.Anji Reddy、B.B. Lohray、Vidya Bhushan、A.Sekar Reddy、P.Hari Kishore、V.Venugopal Rao、V. Saibaba、A.C. Bajji、B.M. Rajesh、K.Vivekananda Reddy、Ranjan Chakrabarti、R. Rajagopalan

  DOI：10.1016/s0960-894x(98)00159-0

  日期：1998.5

  Several thiazolidinediones having antioxidant moities in their structural motif have been synthesised and evaluated for their euglycemic and hypolipidemic activities. A few of them have been found to be superior to troglitazone. (C) 1998 Elsevier Science Ltd. All rights reserved.
• Thiazolidinedione derivatives having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP0801063B1

  公开（公告）日：2003-01-15
• US5925656A
  申请人：——

  公开号：US5925656A

  公开（公告）日：1999-07-20
• Novel Antidiabetic and Hypolipidemic Agents. 5. Hydroxyl versus Benzyloxy Containing Chroman Derivatives
  作者：K. Anji Reddy、B. B. Lohray、V. Bhushan、A. Sekar Reddy、N. V. S. Rao Mamidi、P. Papi Reddy、V. Saibaba、N. Jaipal Reddy、A. Suryaprakash、Parimal Misra、Reeba K. Vikramadithyan、R. Rajagopalan

  DOI：10.1021/jm9805541

  日期：1999.8.1

  Several thiazolidinediones having chroman moieties were synthesized and evaluated for their euglycemic and hypolipidemic activities. Some of the analogues having an aminoalkyl group as a linker between the chroman ring and 4-[5-(2,4-dioxo-1,3-thiazolidinyl)methyl]phenoxy moiety seem to be better than troglitazone. In vitro transactivation assays of PPAR gamma have been carried out with these glitazones to understand their molecular mechanism. For the first time we have found that some of the unsaturated thiazolidinediones are superior to their saturated counterpart in the in vivo assay. A more potent thiazolidinedione analogue than troglitazone is reported. Pharmacokinetic studies have shown that protection of the OH group in the chroman moiety leads to a decrease in metabolism, thereby resulting in a superior pharmacological profile.